

Special Issue

Therapeutic Cancer Vaccines: Advances, Challenges, and Future Directions

Message from the Guest Editor

This Special Issue solicits articles that critically analyze the evolving landscape of therapeutic cancer vaccine development, focusing on solid tumors and malignant hematology. It will explore recent research initiatives and clinical trials implementing diverse vaccination strategies. The Special Issue aims to enhance our understanding of how cancer vaccines can improve treatment outcomes, whether administered alone or combined with standard of care therapy and/or immunotherapy. This Special Issue will encompass a comprehensive overview of the current research landscape, highlighting completed and ongoing clinical trials, alongside insights from recognized experts in the field. It will detail various vaccination strategies, analyze the challenges and obstacles encountered, including issues related to efficacy and the specific patient populations that may respond favorably to vaccines, and delineate future directions. It includes, but are not limited to, the following topics:

- Therapeutic vaccines in solid tumors
- Therapeutic vaccines in malignant hematology
- Immunotherapy and cancer vaccines
- Cancer vaccine clinical trials

Guest Editor

Prof. Dr. Erminia Massarelli

Department of Medicine, University of Texas at Tyler School of Medicine, 11937 US Hwy 271, Tyler, TX 75799, USA

Deadline for manuscript submissions

31 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/241143

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).